Precision Treatment of Patients With GI Cancer Using Pre-emptive <i>DPYD</i> Genotyping/Phenotyping Plus Pharmacokinetic-Guided Dosing of 5-Fluorouracil
The current CPIC guidelines are overly conservative for c.1236G>A/HapB3 and most p.D949V variants. A 75% starting dose is more appropriate for most c.1236G>A/HapB3 carriers. We recommend 5-FU therapeutic drug monitoring in all patients with <i>DPYD</i> variants to achieve optimal 5-FU exposure.
Authors
- Jan Gerard Maring (ORCID: https://orcid.org/0009-0009-8533-9233)
- Daphne den Besten-Bertholee (ORCID: https://orcid.org/0000-0002-7953-1714)
- René Galien
- Jan Willem B. de Groot (ORCID: https://orcid.org/0000-0002-1043-5011)
- Dirk Jan A. R. Moes (ORCID: https://orcid.org/0000-0003-3219-253X)
- Richard M. Brohet (ORCID: https://orcid.org/0000-0003-4472-9322)
- André B. P. Kuilenburg (ORCID: https://orcid.org/0000-0002-7989-4910)
- Pierre M. Bet (ORCID: https://orcid.org/0000-0001-6735-7379)
- Maarten J. Deenen (ORCID: https://orcid.org/0000-0002-4389-6420)
- Helle-Brit Fiebrich-Westra
- Christina Haroun
Institutions
- Radboud University Nijmegen (NL)
- University of Groningen (NL)
- Leiden University Medical Center (NL)
- Catharina Ziekenhuis (NL)
- Isala (NL)
- Amsterdam University Medical Centers (NL)
- Vrije Universiteit Amsterdam (NL)
Publication Details
- Journal
- JCO Precision Oncology
- Published
- 2025-06-06
- DOI
- https://doi.org/10.1200/po-25-00062
- Citations
- 5
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 5.23